Skip to main content

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

Written by Nika Shapouri on . Posted in Client News.

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]